TIN816 70 mg lyophilisate powder

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Acute Kidney Injury Due to Sepsis

Phase 2

Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

CompletedNCT05507437

Novartis PharmaceuticalsAcute Kidney Injury Due to Sepsis

Start: 2022-11-22End: 2024-04-25Updated: 2025-12-04

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

CompletedNCT05996835

Novartis PharmaceuticalsAcute Kidney Injury Due to Sepsis

Start: 2024-01-18End: 2026-05-14Updated: 2026-07-29